With all the chaos and trauma around the world, scientists around the world are continuing to study two drugs — chloroquine and hydroxychloroquine.
As these drugs only seem to a potential fit to cure pneumonia to a certain degree. Coronavirus is a vast dreaded virus that is airborne. Looks like the recent doctors claim that there are ample side effects with these so-called potential drugs to fight COVID – 19.
The safety measures!
Though the potential of the two, chloroquine and hydroxychloroquine differ but with the matters of the heart, it has to be safer!
According to Dr Paul Offit, director of the Vaccine Education Center and an attending physician in the Division of Infectious Diseases at Children’s Hospital of Philadelphia.
He claims that there is no specific drug that enables the proper medication to fight COVID – 19 completely. Parallel to our government, US food and drug administration has issued an emergency use authorization for the two drugs to treat those who have been hit with the deadly virus!
“In a better world, if we weren’t so panicked about this virus, we would wait and see if this drug had some value other than the President declaring that it has some value,” Offit said. “If someone’s sick you can still hurt them.”
The drug chloroquine is similar to hydroxychloroquine, but hydroxychloroquine has been called “a less toxic derivative” of chloroquine.
“Hydroxychloroquine has been used at least in the more developed part of the world very extensively for the treatment of lupus and such and it’s much safer,” said Dr William Schaffner, a professor of preventative medicine and infectious disease at Vanderbilt University School of Medicine in Nashville.
He added, “but there is this residual concern.”
Looks like the hydroxychloroquine, in particular, is a big game-changer in the treatment of COVID – 19. The president of the United States, Donald Trump seem to have played around with the drugs without any advancement in research.
One of the military doctors reported and warned claiming that these specific drugs might have toxic side effects & can lead to cardiac complications.
FDA Commissioner Dr Stephen Hahn said during an appearance on “Fox & Friends” Tuesday morning that there are still some questions that need to be answered around the safety and efficacy of the drug hydroxychloroquine as a possible treatment for COVID-19.
“There are some reports that hydroxychloroquine has some effectiveness in this disease. They aren’t definitive yet but that’s why these clinical trials are so important,” Hahn said, adding that a “fairly large-scale trial” is already underway at the National Institutes of Health.
Hahn legit reported that “I think it’s important to point out that the evidence supports performing these trials to ask the question,“. “And we really look forward to seeing those data to look at the safety and efficacy of this approach.”
Chloroquine is big in Brazil
Here’s why? Even small doses of chloroquine have led to early death in Brazil! A preliminary study out of Brazil on the use of chloroquine diphosphate to treat patients with COVID-19 symptoms ended early after several patients died and researchers found that a high dose of the drug was associated with a severe type of arrhythmia or irregular heartbeat.
The study, which has not yet been published in a peer-reviewed medical journal but was published to the online medical server medRxiv on Saturday, has been submitted to a medical journal for publication, Dr Marcus Lacerda, the study’s principal investigator and a researcher at the institution Fiocruz in Brazil, told CNN in an email on Monday.
The pre-print study included 81 patients who were hospitalized with severe respiratory syndrome in Manaus, Brazilian Amazon. Patients were enrolled in the study before receiving laboratory confirmation of Covid-19, but Lacerda said that 75% of the patients ended up confirmed and the others were “very likely” but their tests came out negative.
For the trial, patients either received a high dose of chloroquine, at 600mg twice daily for 10 days for a total dose of 12g, or they received a low dose at 450mg for five days, twice daily only on the first day, for a total dose of 2.7g. All patients also received the antibiotics ceftriaxone and azithromycin as part of their treatment. A limitation of the study is that there were no patients receiving a placebo.